Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862946 | 1.00 | USP30 (0.46) | USP30MEN1KMT2AGPR119ALOX5AP | |
| SCHEMBL28834045 | 1.00 | USP30 (0.46) | USP30MEN1KMT2AGPR119ALOX5AP | |
| SCHEMBL28834262 | 0.87 | USP30 (0.48) | USP30GPR119JAK2JAK1PRMT5 | |
| SCHEMBL29862921 | 0.87 | USP30 (0.48) | USP30GPR119JAK2JAK1PRMT5 | |
| SCHEMBL29862815 | 0.87 | USP30 (0.48) | USP30GPR119JAK2JAK1PRMT5 | |
| SCHEMBL28834263 | 0.87 | USP30 (0.48) | USP30GPR119JAK2JAK1PRMT5 | |
| SCHEMBL28834334 | 0.87 | USP30 (0.48) | USP30GPR119JAK2JAK1PRMT5 | |
| SCHEMBL23360042 | 0.86 | SMO (0.41) | JAK2JAK1 | |
| SCHEMBL23360044 | 0.86 | SMO (0.41) | JAK2JAK1 | |
| SCHEMBL28834232 | 0.84 | USP30 (0.52) | USP30MEN1KMT2AGPR119JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| CN-114867719-A | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2022-08-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | USP30 1231/4885MEN1 2004/4885KMT2A 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.